Diagnosis of type 1 vs. 2A and 2M von Willebrand disease

Haemophilia

Volumn 18, Issue 1, 2012, Pages

  Favaloro, E J ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; COLLAGEN BINDING PROTEIN; DESMOPRESSIN; RISTOCETIN;

CLINICAL PRACTICE; DIFFERENTIAL DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LABORATORY TEST; LETTER; PHYSICIAN; PRIORITY JOURNAL; RISK; THROMBOCYTE; VON WILLEBRAND DISEASE; VON WILLEBRAND DISEASE TYPE 2A; VON WILLEBRAND DISEASE TYPE 2M;

HEMATOLOGIC TESTS; HUMANS; PRACTICE GUIDELINES AS TOPIC; VON WILLEBRAND DISEASE, TYPE 1;

EID: 84355161761     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2011.02628.x     Document Type: Letter

References (10)

1. Dutt T, Burns S, Mackett N, Benfield C, Lwin R, Keenan R. Application of UKHCDO 2004 guidelines in type 1 von Willebrand disease - a single centre paediatric experience of the implications of altered or removed diagnosis. Haemophilia 2011; 17: 522-6.
2. Laffan M, Brown SA, Collins PW et al. The diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organisation. Haemophilia 2004; 10: 199-217.
3. Favaloro EJ, Bonar R, Kershaw G et al. Reducing errors in identification of von Willebrand disease: the experience of the Royal College of Pathologists of Australasia Quality Assurance Program. Semin Thromb Hemost 2006; 32: 505-13.
4. Favaloro EJ. Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD) - a rebuttal. J Thromb Haemost 2008; 6: 1999-2001.
5. Favaloro EJ. Detection of von Willebrand disorder and identification of qualitative von Willebrand factor defects: Direct comparison of commercial ELISA-based 'VWF:Activity' options. Am J Clin Pathol 2000; 114: 608-18.
6. Nitu-Whalley IC, Riddell A, Lee CA et al. Identification of type 2 von Willebrand disease in previously diagnosed type 1 patients: a reappraisal using phenotypes, genotypes and molecular modelling. Thromb Haemost 2000; 84: 998-1004.
7. Chandler WL, Peerschke EI, Castellone DD, Meijer P, on behalf of the NASCOLA Proficiency Testing Committee. von Willebrand factor assay proficiency testing: the North American Specialized Coagulation Laboratory Association Experience. Am J Clin Pathol 2011; 135: 862-8.
8. Riddell AF, Jenkins PV, Nitu-Whalley IC, McCraw AH, Lee CA, Brown SA. Use of the collagen-binding assay for von Willebrand factor in the analysis of type 2M von Willebrand disease: a comparison with the ristocetin cofactor assay. Br J Haematol 2002; 116: 187-92.
9. Favaloro EJ. Towards a new paradigm for the identification and functional characterisation of von Willebrand disease. Semin Thromb Hemost 2009; 35: 60-75.
10. Favaloro EJ. von Willebrand disease. Local diagnosis and management of a globally distributed bleeding disorder. Semin Thromb Hemost 2011; 37: 440-55.